Welcome to our dedicated page for Dynavax Technolo news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technolo stock.
Dynavax Technologies Corporation (Nasdaq: DVAX) generates a steady flow of news as a commercial-stage biopharmaceutical company focused on vaccines for infectious diseases. News coverage commonly highlights developments related to its adult hepatitis B vaccine HEPLISAV-B®, its CpG 1018® adjuvant platform, and a growing pipeline of adjuvanted vaccine candidates.
Investors and observers following DVAX news will see regular updates on financial results, including quarterly earnings releases filed via Form 8-K, where Dynavax reports HEPLISAV-B net product revenue, total revenues, and adjusted EBITDA, along with commentary on market share trends in the U.S. adult hepatitis B vaccine market. These releases often include forward-looking guidance and discussion of capital allocation decisions such as share repurchase authorizations.
Another major category of Dynavax news involves clinical and pipeline milestones. The company issues press releases on topline data from its Phase 1/2 shingles vaccine trial for Z-1018, describing immunogenicity, tolerability and head-to-head comparisons with Shingrix®. Additional updates cover progress in its plague vaccine program funded by the U.S. Department of Defense, its pandemic influenza adjuvant program using CpG 1018 with H5N1 influenza vaccine, and its investigational Lyme disease vaccine candidate.
Corporate and strategic news items include participation in healthcare investor conferences, announcements of conference calls and webcasts, and collaboration agreements. Notably, Dynavax and Vaxart announced an exclusive license and collaboration for an investigational oral COVID-19 vaccine candidate, and Sanofi has announced an agreement to acquire Dynavax through a cash tender offer and subsequent merger, subject to customary conditions.
By tracking the DVAX news feed, readers can monitor how Dynavax’s commercial performance, clinical data, collaborations and corporate transactions evolve over time. This page aggregates company press releases and related disclosures so that users can review financial updates, pipeline progress and strategic announcements in one place.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 94,000 shares and restricted stock units (RSUs) for 2,500 shares to 5 newly-hired employees. The stock options were awarded on January 4, 2022, at an exercise price of $13.40, matching the closing stock price on that date. The stock options have a 7-year term and follow a vesting schedule of one-third after one year and the remainder monthly over two years. The RSUs will vest one-third annually. These grants were made to comply with Nasdaq Listing Rule 5635(c)(4).
Dynavax Technologies (Nasdaq: DVAX) has announced that CEO Ryan Spencer will present at the H.C. Wainwright Virtual BioConnect 2022 Conference scheduled for January 10-13, 2022. The on-demand presentation will be accessible starting January 10, 2022, at 7:00 a.m. E.T. on the company’s website under the 'Events & Presentations' section. Dynavax is a biopharmaceutical firm specializing in developing vaccines, including HEPLISAV-B®, which is approved for preventing hepatitis B infections in adults.
Dynavax Technologies Corporation (DVAX) announced that Biological E's COVID-19 vaccine, CORBEVAX™, received emergency use approval from India's Drugs Controller General. This vaccine uses Dynavax's CpG 1018® adjuvant. The companies have a commercial supply agreement for 300 million doses, bolstering Dynavax's supply capabilities for 2022 and beyond. The CpG 1018 adjuvant is proven to enhance vaccine immune response and is included in multiple vaccines, contributing over $197 million in revenue in 2021.
Sensorion (Euronext Paris: ALSEN) has appointed Scott D. Myers as Chairman of its Board of Directors, succeeding Edwin Moses who is stepping down on
Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Elaine Sun to its Board of Directors. Ms. Sun, who brings over 20 years of experience in life sciences and investment banking, has previously held significant roles at Halozyme and SutroVax. CEO Ryan Spencer expressed confidence in her expertise to enhance Dynavax's strategic direction, particularly in expanding HEPLISAV-B market share and advancing their CpG 1018 adjuvant development. The announcement highlights Dynavax's commitment to innovative vaccine solutions against infectious diseases.
Dynavax Technologies Corporation (Nasdaq: DVAX) announced the grant of nonstatutory stock options for 58,500 shares to 5 new employees on December 1, 2021. The options have an exercise price of $15.11 per share, aligning with the closing stock price on that date. Each option has a 7-year term and will vest over three years. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement to employment under the 2021 Inducement Award Plan.
Dynavax Technologies Corporation (NASDAQ: DVAX) announced that CEO Ryan Spencer will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on November 30 at 2:40 p.m. E.T. The live audio webcast can be accessed via the company's Investors section. A replay will be available for 30 days post-event. Dynavax is known for its HEPLISAV-B® vaccine approved for hepatitis B prevention and is advancing its CpG 1018 adjuvant for various vaccines.
Dynavax Technologies Corporation (Nasdaq: DVAX) reported strong financial results for Q3 2021, achieving total revenue of $108.3 million, driven by substantial growth in its HEPLISAV-B vaccine and CpG 1018 adjuvant. Revenue for HEPLISAV-B rose to $22.7 million, up from $11.6 million year-over-year, with market share increasing to 33.5%. CpG 1018 revenue soared to $84.3 million, up from $1.7 million in Q3 2020. Net loss widened to $28.4 million, reflecting a significant non-cash loss related to warrant liability. The company ended the quarter with $414.2 million in cash and equivalents.
On November 2, 2021, Dynavax Technologies Corporation (DVAX) announced the granting of nonstatutory stock options for 5,000 shares to a newly hired employee. The options, granted at an exercise price of $20.56 per share, equal the stock's closing price on the grant date. Each option has a 7-year term and vests over three years. This grant adheres to Nasdaq Listing Rule 5635(c)(4) and is part of Dynavax's 2021 Inducement Award Plan aimed at incentivizing new hires.
Dynavax Technologies Corporation (Nasdaq: DVAX) has appointed Scott Myers as a new member and Chairman of its Board of Directors, succeeding Dr. Andrew Hack. Myers brings nearly three decades of experience in the pharmaceutical and medical technology sectors. Under his leadership, Dynavax aims to enhance growth, focusing on its key products: HEPLISAV-B and CpG 1018. Dr. Hack remains on the board, providing continued guidance. This leadership change is expected to strengthen the company's strategic direction in vaccine development.